FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine

Paris, France, January 19, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the approval by US FDA of the expansion of the Prima System* US feasibility study to include Stanford Medicine as a clinical site. This third location for the study at the Byers Eye Institute at Stanford Medicine joins the original two locations at the UPMC Eye Center in Pittsburgh and the Bascom Palmer Eye Institute in Miami.